For the quarter ended September 30, 2026, consensus estimates project revenue of $382.42 million and earnings per share of $0.79, while the stock currently trades at $38.88 against an average analyst target of $47.00.
Investors are primarily focused on the operational performance and integration of the Zoetis Medicated Feed Additive (MFA) portfolio, which has materially expanded Phibro's animal health platform.
Market participants are also monitoring the company's ability to maintain margin expansion despite regulatory headwinds for antimicrobial products in Brazil and ongoing restructuring costs from manufacturing consolidations. Additionally, analysts are watching for signs of improved free cash flow as inventory levels normalize following significant builds earlier in the year.